ArticleCNS neuroscience & therapeutics2026
Midazolam Exerts Sedative Effects by Differentially Modulating Cortical Pyramidal Neurons and PV Interneurons.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsMidazolam is a sedative that acts on γ-aminobutyric acid type A receptors, but whether its effects are region-specific, especially in the neocortex, and the mechanisms underlying these effects remain unclear.
methodsUsing microendoscopic Ca
resultsMidazolam dose-dependently suppressed pyramidal neurons more potently in the AC than in the ACC (Evoked: pyramidal neurons: 0.65 ± 0.30 vs. 1.36 ± 0.34, p < 0.0001; Spontaneous: pyramidal neurons: 1.49 ± 0.48 vs. 2.25 ± 0.42, p = 0.0006). In slices, midazolam reduced the action potential firing of pyramidal neurons in a concentration-dependent manner, with greater sensitivity in the AC. In contrast, PV
conclusionMidazolam suppresses cortical excitatory neurons in a region- and cell-type-dependent manner that is associated with differential expression of GABRA1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.